Riskpilot← Back to searchSign inGet full accessOubari läkarekonsult AB
ABActiveOrg 5569489205Allmogevägen 3 Lgh 1404Medical specialists activities · NACE 8622Est. 20130 employees
Revenue 2024
SEK 1M
+47% vs 2023
EBITDA margin
50.9%
+122% vs 2023
Equity ratio
69.7%
Financial strength
Net profit 2024
SEK 312K
+2% vs 2023
| Revenue | SEK 1M | +47% |
| EBITDA | SEK 527K | +122% |
| Net profit | SEK 312K | +2% |
| Total assets | SEK 3,5M | +11% |
| Equity | SEK 2,5M | +5% |
| Employees | 0 | — |
Legal name
Oubari läkarekonsult AB
Org number
5569489205
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
14 november 2013
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget bedriver konsultverksamhet inom ögonsjukdomar och allmän medicin samt därmed förenlig verksamhet. Bolaget bedriver även estetiska behandlingar samt därmed förenlig verksamhet.
Address
Allmogevägen 3 Lgh 1404
Email
emanuel@oubari.net
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 929 | 950 | 694 | 702 | 1 035 |
| Staff expenses | — | — | −1 | −10 | −14 |
| EBITDA | 363 | 499 | 245 | 237 | 527 |
| Depreciation & amort. | −30 | −0 | — | — | — |
| EBIT | 333 | 499 | 245 | 237 | 527 |
| Net financials | — | — | 26 | 5 | 6 |
| Profit before tax | 248 | 372 | 453 | 395 | 399 |
| Tax | −56 | −79 | −100 | −89 | −87 |
| Net profit | 192 | 293 | 353 | 306 | 312 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 3 127 | 3 283 | 3 251 | 3 177 | 3 520 |
| Equity | 1 959 | 2 069 | 2 234 | 2 345 | 2 452 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 416 | 335 | 320 | 287 | 389 |
| Total debt | 416 | 335 | 320 | 287 | 389 |
EBITDA margin
50.9%
This company
15.8%
Market median
+222% vs market
20202024
Equity ratio
69.7%
This company
38.2%
Market median
+82% vs market
20202024
Return on equity
12.7%
This company
18.4%
Market median
+31% vs market
20202024
Net profit margin
30.2%
This company
8.1%
Market median
+273% vs market
20202024
Asset turnover
0.29×
This company
1.12×
Market median
-74% vs market
20202024
Debt / equity
0.44×
This company
0.62×
Market median
+29% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2020 | |
| Deputy Board Member | 2025 | |
| Former (2) | ||
| Deputy Board Member | 2022 – 2025 | |
| Deputy Board Member | 2020 – 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Oubari läkarekonsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Emanuel Oubari | Board of Directors | 0 companies |
| Jonny Kass Kawo | Deputy Board Member | 0 companies |
| David Eyad Issa | Deputy Board Member | 0 companies |
| Tyoudra Dawod | Deputy Board Member | 0 companies |